Areas covered: This review summarizes the landscape of drugs under development for HER2 positive metastatic breast cancer, as antibody-drug conjugates, monoclonal anti-HER2 antibodies, bispecific antibodies, or
Official Answer by Drugs.com Quercetin is an antioxidant and belongs to a group of plant pigments called flavonoids. It is found naturally in many fruits, vegetables, flowers, bark, and leaves but is not made in the human body. Studies show quercetin may help to protect against many health ...
Kinase inhibitorsSmall molecule therapeuticsMedicine(GeneralBackground Until late in the 20th century, the therapy of rheumatic diseases relied on the use of drugs that had been developed through empirical approaches without detailed understanding of the molecular mechanisms involved. That approach changed ...
For example, there are many causes of lung cancer, but only people who have a variant within epithelial growth factor receptor (EGFR) respond to treatment with tyrosine kinase inhibitors [6]. Cohort study is a very effective approach for PM. For instance, the well-known Framingham Heart Study...
When we are trying to discuss disease modification right now, I see it like chronic myeloid leukemia before the era of tyrosine kinase inhibitors. We used to discuss, "Does it matter if you have a 1-log difference or 2-log difference in your BCR-ABL?" Whereas now, who cares about that...
TNF-α inhibitors include etanercept, infliximab, golimumab and adalimumab. These drugs are generally used to control inflammatory disorders such as rheumatoid arthritis (RA) or inflammatory bowel disease.10 The most common adverse effects from TNF-α blockers are injection and infusion site reactions...
In acute leukemia, currently available chemotherapy drugs promote cell death and demonstrate clinical benefit, but relapse and subsequent chemotherapy resistance is common. Increasing preclinical data suggest that autophagy is active in leukemia as a means of promoting cell survival in response to ...
The introduction of tyrosine kinase inhibitors (TKI) has dramatically changed the outcome of chronic myeloid leukemia (CML). Over the last decade, imatinib positioned itself as the gold standard of care, until second-generation TKIs were introduced as first-line treatment. Multiple therapeutic options...
Inhibitors of T-cell activation and signaling are still in preclinical development. The most interesting inhibitors of T-cell proliferation include inhibitors of the Janus protein tyrosine kinase, JAK3, and FK778, a leflunomide analog. Chemokines play an important role in rejection by virtue of ...
; third, what are the critical protein modifications involved in T-cell activation; and finally, what is the role of hapten-specific T-cells in the iatrogenic disease? These questions will become increasingly important as more and more targeted covalent binding inhibitor drugs are approved for ...